ClinicalTrials.gg
CompletedNCT01944410TBCUpdated Oct 7, 2014

Use of PRP in Treatment of Mandibular Traumatic Bone Cyst

A Phase 1 interventional study of PRP injection in Traumatic Bone Cyst, sponsored by Shiraz University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 15 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-10-07.

Sponsored by Shiraz University of Medical Sciences · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
15 Years to 65 Years
Sex
All
01

Study summary

The traumatic bone cyst (TBC) is an infrequent nonepithelial lined cavity of the jaws, which was first expressed by lucassin 1929, the lesion has attracted a great deal of interest in the dental literature, but its pathogenesis is still not evidently recognized. It determines a bone cavity of irregular shape which appears like a cyst on a radiograph, and histopathologically there are no elements to confirm a diagnosis of a cysts. TBC the international histological classification assumed by the World Health Organisation for odontogenic tumours utilizes the term "solitary bone cyst", nevertheless the term "traumatic bone cyst" (TBC) is more extensively used in the literature. The WHO classification explains TBC as a non-neoplastic osseous lesion because it demonstrates no epithelial lining, which differentiates this lesion from the true cysts. There is general conformity that most traumatic bone cysts present without symptoms or signs. Seldom, expansion of the cortical plate may occur with extraoral swelling, less commonly there may erosion through the cortical bone may take place.' Teeth in the area of involved bone usually remain vital, without root resorption or tooth mobility. Treatment of traumatic bone cysts has included surgical exploration and curettage to motivate bleeding within the bony cavity,' packing of the cyst cavity with Gelfoam which has been saturated with thrombin and penicillin, and bone grafting based on previous study Injection of autogeneic blood into the bony cavity of a traumatic bone cyst was followed by rapid resolution of the lesion.

Platelet-rich plasma (PRP) is a rich source of growth factors. The growth factors present in PRP are familiar, including transforming growth factor-_ (TGF-_1 and TGF-_2), vascular endothelial growth factor, 3 isomers of platelet-derived growth factor (PDGF-__,PDGF-__, and PDGF-__), and endothelial growth factor. These growth factors are considered to have the capacity to accelerate chemotaxis, mitogenesis, angiogenesis, and synthesis of collagen matrix and support tissue repair when applied on bone wounds. Due to this high platelet content, PRP has been used in orthopaedic surgery, oral implantology, and periodontics with the aim of making the repair process as fast and natural as possible, as it can potentially afford considerable tissue improvement in bone and soft tissue in a similar way. PRP is easily acquired, rich in cell signalling molecules, completely autogenous and can be obtained from minimal blood volumes.the purpose of the present study is to determine the efficacy of PRP in the treatment of mandibular TBC.

Read the detailed description

The study sample consisted of 12 young adult volunteers presenting with TBC of mandible. Local ethical committee approval will be obtained before the trial starts. Laboratory tests (complete blood count, glucose, creatinine, platelets, lipid profile) were performed for all patients. These tests provided an important overview of patient health and a baseline for analysis of the prognosis of PRP use. The process for obtaining PRP basically consists of collection of a 20-mL sample of blood, centrifugation of this sample for 8 min, isolation of a 1-mL aliquot of plasma collected near the erythrocyte fraction. Surgical procedure includes: surgical exploration and injection of PRP to stimulate bone regeneration within the bony cavity . Bone repair was assessed by panoramic X-rays obtained at 2, 4, and 6 months postoperatively. Bone density was measured by area histogram analysis.

02

Conditions studied

  • Traumatic Bone Cyst

Browse trials for

Keywords

  • PRP
  • TBC
  • Treatment
03

In context

Bone Cysts

18 studies on the registry are indexed under Bone Cysts; 5 are open to participants now.

This study's planned enrollment of 12 is below the median of 17 across 10 interventional studies indexed under Bone Cysts.

Browse Bone Cysts studies →

Lead sponsor

Shiraz University of Medical Sciences is the lead sponsor of 130 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Traumatic Bone cyst diagnosed with panoramic X-Ray and histopathologic evaluation

  • Intact cyst wall with high risk for fracture
  • Patients of both sexes between 15 to 65 year's old
  • Patients who are willing for evaluation in 2,4 and 6 months after surgery Patients who are willing for Laboratory tests . Provided written consent form
  • Patients who agree to take xray in 2,4 and 6 months after surgery for radiographic evaluation

Exclusion criteria

Exclusion Criteria:

  • Patients who unable to undergo oral surgery
  • Patients using systemic drugs or presenting a medical history positive for any systemic pathology history of to any component used in the methodology Pregnant patients
  • Smokers
  • Patients who can not continue the study for private or social reasons
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    traumatic bone cyst

    Patients with traumatic bone cyst defect are injected with PRP

    Biological: PRP injection

Interventions

  • BiologicalPRP injection

    injection of PRP to traumatic bone cyst defect

    Also known as: growth factor injection

06

What researchers measure

Primary outcomes

  1. Fulfill bone cyst defect

    change in size of the defect of bone will be measured by millimeter on radiographic examination in 2,4.6 months after PRP injection and will be compared with initial size of the defect

    Time frame: : 6 months

Secondary outcomes

  1. effect of PRP

    Evaluate effect of PRP injection to fulfill the defect of bone cyst and decrease size of the lesion

    Time frame: 6 months

07

Study locations

1 site
  • RE
    Shiraz, CMF ward , Chamran hospital , Chamran avenue., Iran, Islamic Republic of
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01944410
Responsible party
Reza Tabrizi (oral and maxillofacial surgeon, Shiraz University of Medical Sciences) — Principal investigator
First posted
Sep 17, 2013
Start date
Jan 2013
Primary completion
Jan 2014
Completion
Apr 2014
Last update
Oct 7, 2014

Study contacts

Reza Tabrizi, DMD
study chair · SUMS
Reza Tabrizi, DMD
study director · SUMS
Shole shahidi, DDS
study director · SUMS
Touba Karagah, DMD
principal investigator · SUMS
Nasibeh Zare, DDS
principal investigator · SUMS

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Platelet rich plasma

Start the discussion